



Invest like a pro, with the pros.



www.capitalideasmedia.com

Morning Need to Know

Getting you ready for your investing day

May 25, 2020

**Written & curated by Mark Bunting, Publisher,
Capital Ideas Media**



CANADIAN ANALYSTS' CALLS

Medexus Pharmaceuticals (TSXV:MDP). Mackie Research lowers the price target to \$6.30 (Canadian) from \$7.60, which implies 152% upside, "fine tunes" its financial estimates and maintains a "speculative buy" rating.

WELL Health Technologies (TSX:WELL). Beacon Securities moves the target to \$3.50 from \$2.50, updates its financial estimates and maintains a "buy" rating. Beacon has provided investment banking services to WELL within the last 12 months. Eight Capital also raises the target to \$3.50 from \$2.50.

CAE (TSX:CSE). Raymond James slashes the target to \$19 from \$40 and maintains a "market perform" rating.



U.S. ANALYSTS' CALLS

None due to the U.S. holiday.



STOCKS THAT MAY MOVE

Vermilion Energy (TSX:VET) said president, CEO and director Anthony Marino is stepping down.

MARKETS

Canadian stocks will go it alone for most of today with the U.S. markets closed for Memorial Day which typically means light volume trading. European stock indices are mostly higher with London financial markets closed for a holiday.

CURRENCIES

The Canadian dollar is up slightly at 0.7150 (U.S.).

COMMODITIES

West Texas Intermediate crude oil is up 0.8% to \$33.52 a barrel.

Gold is down by 0.5% to \$1,727 an ounce.



Find out why [Spotify's \\$100-million deal](#) with Joe Rogan means "game, set, match" in its fight with Apple.

Please email questions, comments or concerns to:
customercare@capitalideasresearch.com

Access, insight and ideas.

Mark Bunting
Publisher,
[Capital Ideas Media](#)

www.capitalideasmedia.com



The information and recommendations made available here (“Information”) by CIR and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Capital Ideas Research will be liable for any losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and reading this note, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.

CIR is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.

In no event will CIR be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.

This is not an investment advisory, and should not be used to make investment decisions. Information in CIR is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied

solicitation to buy or sell securities. The writers and editors of CIR may have positions in the stocks discussed above and may trade in the stocks mentioned. Don't consider buying or selling any stock without conducting your own due diligence.

Copyright © 2016 Capital Ideas Research, All rights reserved.

You are receiving this email because you are part of our investment network.

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Capital Ideas Research · HSBC Bank Place · 10250 101 Street Suite 1803 · Edmonton, Alberta T5J 3P4 · Canada